FITC anti-C1q Primary Antibody

Skip to Content


Skip over Generic Navigation

  • Select your country:
DIAGNOSTICS F. Hoffmann-La Roche Ltd

FITC anti-C1q Primary Antibody

FITC anti-C1q Primary Antibody, kidney, 400x
Catalog Number:760-2688
Ordering Code:05267994001
Quantity:50 tests
Controls:Frozen, Diseased Skin or Diseased Renal Tissue
Clone Name:Polyclonal
Species:Goat
Regulatory Status:IVD


This antibody is intended for in vitro diagnostic (IVD) use. Ventana Medical Systems, Inc. (Ventana) Systems FITC anti-C1q (complement 1q) Primary Antibody is a goat derived polyclonal antibody labeled with fluorescein and specifically directed against human C1q. This reagent should be used in conjunction with a panel of antibodies to aid in the identification of complement 1q in C1q target tissue (e.g., in the diagnosis of renal or dermal pathologies). FITC anti-C1q is intended for laboratory use to qualitatively stain sections of frozen tissue on a Ventana automated slide stainer. The clinical interpretation of any staining, or the absence of staining, must be complemented by morphological studies and evaluation of proper controls. Evaluation must be made by a qualified pathologist within the context of the patient’s clinical history and other diagnostic tests. Prescription only.


Health Care Provider Notice
X
This website is intended for healthcare professionals only.

The content on this website is intended for healthcare professionals only. Information intended for the general public can be found on Roche.com. Please confirm that you are a medical professional before accessing the content of this website.

Yes, I hereby certify that I am a healthcare professional. Continue
Third-Party Link Disclosure
X
Disclosure for Links to Third-Party Websites

You are now leaving the Roche website. The site you are about to visit is operated by third-parties. The link to this site neither makes nor implies any representation or warranty for any products or services offered on a third-party site and is intended only to enable convenient access to the third-party site and for no other purpose.

Continue